AtheroGenics Drops AGIX-4207 After Failed Rheumatoid Arthritis Phase II Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
Placebo yielded a greater ACR 20 response rate than any of three AGIX-4207 dosing arms in the Phase II trial. The company will turn to second-generation compounds that are part of its vascular protectant program.